NASDAQ
16.10.25 | 19:02
16,520 US-Dollar
-2,36 % -0,400
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Arcus Biosciences, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| Mo | Arcus Biosciences stock rises after strong gastric cancer survival data | 1 | Investing.com | ||
| Mo | Arcus Biosciences-Aktie steigt nach starken Überlebensdaten bei Magenkrebs | 1 | Investing.com Deutsch | ||
| Mo | Arcus Biosciences rises on results from domvanalimab cancer study | 1 | Seeking Alpha | ||
| Mo | Gilead Sciences/Arcus Biosciences' Investigational Cancer Drug Shows Overall Survival Of Around 27 Months | 24 | Benzinga.com | ||
| Mo | Arcus Biosciences to present promising gastric cancer survival data | 1 | Investing.com | ||
| 07.10. | Truist Securities raises Arcus Biosciences stock price target on casdatifan potential | 1 | Investing.com | ||
| 07.10. | Casdatifan-Potenzial: Truist Securities hebt Kursziel für Arcus Biosciences an | 1 | Investing.com Deutsch | ||
| ARCUS BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 07.10. | How Arcus Biosciences Aims To Take On Merck In Cancer Treatment | 9 | Investor's Business Daily | ||
| 06.10. | Why Is Arcus Biosciences Stock Trading Higher On Monday? | 1 | Benzinga.com | ||
| 06.10. | Arcus Biosciences stock soars after promising kidney cancer drug data | 1 | Investing.com | ||
| 06.10. | Arcus Biosciences, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 10.09. | Arcus Biosciences auf Morgan-Stanley-Konferenz: Strategische Prioritäten bis 2026 | - | Investing.com Deutsch | ||
| 09.09. | Arcus Biosciences: Strategische Positionierung im Markt für Nierenzellkarzinome | 2 | Investing.com Deutsch | ||
| 18.08. | Mizuho raises Arcus Biosciences stock price target on casdatifan potential | 2 | Investing.com | ||
| 06.08. | Arcus Biosciences, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 10.07. | Arcus Biosciences' cancer drug gets orphan drug status | 1 | Seeking Alpha | ||
| 10.07. | Arcus Biosciences' Quemliclustat Gets Orphan Drug Status For Pancreatic Cancer | - | RTTNews | ||
| 08.07. | Arcus Biosciences February 2025 slides: oncology pipeline progresses despite Q1 miss | 3 | Investing.com | ||
| 01.07. | Arcus Biosciences Presents First Postive Data for Oral Metastatic Kidney Cancer Treatment | 1 | Insider Monkey |
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INFLARX | 1,043 | -2,52 % | InflaRx N.V.: InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement | JENA, Germany, Sept. 12, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system (the "Company")... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 22,040 | -0,99 % | Intellia Therapeutics (NTLA) Soars to New High as Analysts Trigger 'Buy' | ||
| XOMA ROYALTY | 31,800 | -1,24 % | XOMA Royalty Corporation Extends Tender Offer to Acquire LAVA Therapeutics N.V. | EMERYVILLE, Calif. and UTRECHT, The Netherlands and PHILADELPHIA, Oct. 02, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ: XOMA) and LAVA Therapeutics N.V. ("LAVA") (Nasdaq:... ► Artikel lesen | |
| TELIX PHARMACEUTICALS | 9,440 | -0,36 % | Why Bank of Queensland, Jumbo, Santana Minerals, and Telix shares are charging higher today | ||
| BEAM THERAPEUTICS | 27,430 | +0,73 % | Jefferies stuft Beam Therapeutics auf "Buy": Kommende Katalysatoren im Fokus | ||
| CYTOKINETICS | 51,00 | -5,56 % | Cytokinetics, Incorporated: Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) | SOUTH SAN FRANCISCO, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on September 15, 2025 it granted stock options to purchase an aggregate... ► Artikel lesen | |
| ROCKET PHARMACEUTICALS | 3,521 | -3,19 % | FDA Acceptance Of Rocket Pharmaceuticals' Lead Gene Therapy Application Reestablishes Momentum For Stock | ||
| OUTLOOK THERAPEUTICS | 1,188 | -4,27 % | Outlook Therapeutics, Inc.: Outlook Therapeutics Provides Update on Type A Meeting with FDA | ISELIN, N.J., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment... ► Artikel lesen | |
| VANDA PHARMACEUTICALS | 4,620 | 0,00 % | Vanda Pharmaceuticals Inc.: Vanda Pharmaceuticals Announces Collaborative Framework for Resolution of Disputes with the U.S. Food and Drug Administration | WASHINGTON, Oct. 1, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it has agreed on a collaborative framework with... ► Artikel lesen | |
| ROIVANT SCIENCES | 14,615 | +0,21 % | Roivant Sciences auf Rekordhoch: Aktie klettert auf 16,8 USD | ||
| CARTESIAN THERAPEUTICS | 7,900 | +1,94 % | Cartesian Therapeutics, Inc.: Cartesian Therapeutics Announces New Employment Inducement Grant | FREDERICK, Md., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the "Company"), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases... ► Artikel lesen | |
| ADVERUM BIOTECHNOLOGIES | 3,760 | -2,59 % | Adverum Biotechnologies, Inc.: Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | REDWOOD CITY, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that the Compensation Committee of Adverum's Board of Directors granted inducement... ► Artikel lesen | |
| ANNOVIS BIO | 1,766 | +13,79 % | Annovis Bio Inc.: Annovis Announces Novel Biomarker Data in Alzheimer's Patients Supporting Buntanetap's Potential as a Disease-Modifying Treatment | MALVERN, Pa., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative... ► Artikel lesen | |
| QUINCE THERAPEUTICS | 1,995 | +0,76 % | Quince Therapeutics stellt auf Neurologie-Tagung Daten zur Gehfähigkeit bei A-T vor | ||
| VERA THERAPEUTICS | 30,740 | -0,84 % | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BRISBANE, Calif., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on October 6, 2025, the Compensation Committee of the Board of Directors of Vera Therapeutics... ► Artikel lesen |
ARCUS BIOSCIENCES INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 16,520 Euro und damit -2,36 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ARCUS BIOSCIENCES INC finden Sie auf Wallstreet Online.